Low-Dose Oral Interferon Alpha in the Management of Symptomatic HIV-1 Infection
Non-conventional
in En
| AIM
| ID: biblio-1275906
Responsible library:
CG1.1
ABSTRACT
Objectives:
To determine whether symptomatic HIV-1 infected persons will benefit from treatment with low doese oral interferon alpha (IFN). StudyDesign:
This was a randomised ; double-blind; placebo controlled trial.Results:
a total of 560 patients (45male; 55females) were enrolled between May 1991 and July 1992. At entry the baseline characteristic of age; WHO clinical stage; body weight; Karnofsky score and CD4+ cell count between the 2 groups were similar. Patients were followed up to between 30 and 60 weeks. Survival rates and disease progression was analysed using Kaplan-Meier estimation long-rank test and proportional hazards regression. Symptoms on follow up were analysed using logic regression and adjusted relative risk estimates. The details will be presented.Conclusion:
The study did not reveal any significant differences between the group which took IFN and the one on placebo
Search on Google
Main subject:
Organization and Administration
/
Acquired Immunodeficiency Syndrome
/
Interferon-alpha
Type of study:
Clinical_trials
/
Etiology_studies
Language:
En
type:
Non-conventional